Paper36076533
Qingda granule alleviate angiotensin ⅱ-induced hypertensive renal injury by suppressing oxidative stress and inflammation through NOX1 and NF-κB pathways.
Chen D and 12 others. Biomed Pharmacother, 2022. Cited by 19 papers, by iCite.
Cite this record
ConductScience Library. Qingda granule alleviate angiotensin ⅱ-induced hypertensive renal injury by suppressing oxidative stress and inflammation through NOX1 and NF-κB pathways. Papers, record 36076533. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36076533
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Qingda granule alleviate angiotensin ⅱ-induced hypertensive renal injury by suppressing oxidative stress and inflammation through NOX1 and NF-κB pathways.
- PubMed
Topics10
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Angiotensin II | Major topic |
| Hypertension | Major topic |
| Animals | |
| Drugs, Chinese Herbal | |
| Inflammation | |
| Kidney | |
| Mice | |
| NF-kappa B | |
| Nitrogen Oxides | |
| Oxidative Stress |
Source PubMed
Cited by7
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 19 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41867166 | Prognostic value of stress hyperglycemia ratio in critically Ill patients with acute kidney injury: a machine learning-driven retrospective cohort analysis. | Health Inf Sci Syst | 2026 | https://conductscience.org/library/papers/41867166 | PubMed |
| 41035910 | Qingda granule prevents Ang II-induced cardiac hypertrophy via inhibiting NF-κB signaling pathway. | Front Pharmacol | 2025 | https://conductscience.org/library/papers/41035910 | PubMed |
| 40621077 | Ginsenoside Rg5 modulates the TLR4 and BCL-2 pathways by inhibiting NOX1, thereby alleviating inflammation, apoptosis and pyroptosis in hyperuricemia nephropathy. | J Ginseng Res | 2025 | https://conductscience.org/library/papers/40621077 | PubMed |
| 40520190 | Trifolin inhibits the calcium-driven contraction pathway in vascular smooth muscle. | Front Pharmacol | 2025 | https://conductscience.org/library/papers/40520190 | PubMed |
| 39819708 | Qingda Granules alleviate brain damage in spontaneously hypertensive rats by modulating the miR-124/STAT3 signaling axis. | Nan Fang Yi Ke Da Xue Xue Bao | 2025 | https://conductscience.org/library/papers/39819708 | PubMed |
| 39728459 | Antihypertensive Effect of Perla and Esmeralda Barley (Hordeum vulgare L.) Sprouts in an Induction Model with L-NAME In Vivo. | Metabolites | 2024 | https://conductscience.org/library/papers/39728459 | PubMed |
| 38345042 | Current perspectives and trends of the research on hypertensive nephropathy: a bibliometric analysis from 2000 to 2023. | Ren Fail | 2024 | https://conductscience.org/library/papers/38345042 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| NFKB1 | 4790 | PubTator's text mining | https://conductscience.org/library/genes/4790 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36076533
GET https://conductscience.org/api/papers/v1/36076533/authors